PACT Pharma

About PACT Pharma

PACT Pharma, Inc. operates as a clinical-stage biopharmaceutical entity focused on developing personalized adoptive T-cell therapies for solid tumors. The company was established in 2016, emerging from the foundational research of co-founders David Baltimore, Antoni Ribas, and Jim Heath, who harnessed their expertise in immunology and technology to create a new approach to cancer treatment. This venture was initiated within the Parker Institute for Cancer Immunotherapy and is backed by its venture capital firm, Vida Ventures. The company's core technology revolves around a proprietary method to identify the specific genetic mutations driving a patient's cancer and then isolate the T cells from their blood that can recognize these mutations.

The process begins with a blood sample and a tumor biopsy from the patient. PACT Pharma utilizes its high-throughput platform to sequence the tumor's genome, identifying the neoantigens—unique proteins on the surface of cancer cells that can be recognized by the immune system. Simultaneously, they isolate T cells from the patient's blood and identify the specific T cell receptors (TCRs) that can bind to these neoantigens. Using non-viral precision gene editing, specifically CRISPR, these identified TCRs are engineered into a larger population of the patient's own T cells. This creates a personalized army of cancer-fighting cells that are then infused back into the patient, designed to precisely target and eliminate their specific tumor.

The company's business model is centered on the development and eventual commercialization of these bespoke cell therapies. PACT Pharma has progressed its therapies into clinical trials, with its first patient dosed in a Phase 1 clinical trial in 2021 for metastatic solid tumors. While the company has shown promising initial results, it has also faced challenges inherent in the complex field of cell therapy development. In early 2023, PACT Pharma underwent a significant restructuring, which included workforce reductions and the discontinuation of its two wholly owned clinical programs. The company has since shifted its strategy to focus on its precision gene-engineering platform and pursuing partnerships to leverage its technology for future therapeutic development.